By Raghavendar Rao Morthala, Ph.D., General Manager – API R&D, and Rajesh Shenoy, Ph.D., VP R&D and Global Head of API, Piramal Enterprises Limited
Due to the increasingly competitive pharmaceutical industry, speed to market is essential in drug development. Medicinal chemists developing new compounds are faced with the probability that less than 10 percent of drug development programs successfully make it to market. Therefore, they strive to produce as many effective compounds as possible to increase the chances of commercialization. Nevertheless, in this rush to market, you should be aware of critical missteps that can occur during the early development phases, in order to avoid major challenges later during commercial scale-up.